

REVENIO

Revenio Group Corporation: Managers' Transactions –Robin Pulkkinen

Revenio Group Corporation, Managers' transactions, February 16, 2023 at 4.00 p.m. (EET)

Revenio Group Corporation: Managers' Transactions –Robin Pulkkinen

Person subject to the notification requirement

Name: Robin Pulkkinen

Position: Chief Financial Officer

Issuer: Revenio Group Oyj

LEI: 743700127E0FWSXLKK04

Notification type: INITIAL NOTIFICATION

Reference number: 25534/7/6

Transaction date: 2023-02-15

Outside a trading venue

Instrument type: SHARE

ISIN: FI0009010912

Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details (1):

Volume: 1122 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 1122 Volume weighted average price: 0 EUR

For further information, please contact

CFO Robin Pulkkinen, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

www.revenio.fi

Distribution

Nasdaq Helsinki

FIN-FSA

Key media

www.revenio.fi/en

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical

REVENIO

software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group's net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: Managers' Transactions –Robin Pulkkinen](#)